{
    "clinical_study": {
        "@rank": "164736", 
        "arm_group": [
            {
                "arm_group_label": "IdeS", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion"
            }, 
            {
                "arm_group_label": "PBS Buffer", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a first in man study to assess safety and tolerability of the IgG cleaving enzyme\n      Immunoglobuli G degrading enzyme of streptococcus pyogenes (IdeS)."
        }, 
        "brief_title": "Safety Study on IdeS in Healthy Volounteers", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to understand and sign informed consent\n\n          -  BMI 19-30\n\n        Exclusion Criteria:\n\n          -  Clinically significant disease\n\n          -  Positive HIV, hepatistis B or C\n\n               -  Drug abuse\n\n          -  Smoking\n\n          -  Use of medication except paracetamol"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802697", 
            "org_study_id": "11-HMedIdeS-01", 
            "secondary_id": "2012-000969-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "IdeS", 
                "intervention_name": "IdeS", 
                "intervention_type": "Drug", 
                "other_name": "IdeS"
            }, 
            {
                "arm_group_label": "PBS Buffer", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "volunteers", 
        "lastchanged_date": "February 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden", 
                    "zip": "22185"
                }, 
                "name": "Clinical Trial Unit, FoU centrum Sk\u00e5ne, Sk\u00e5ne University hospital"
            }, 
            "investigator": {
                "last_name": "Ulf Malmqvist, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase i Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects", 
        "other_outcome": {
            "measure": "Total IgG concentration", 
            "safety_issue": "No", 
            "time_frame": "64 days"
        }, 
        "overall_contact": {
            "email": "lena.winstedt@hansamedical.com", 
            "last_name": "Lena Winstedt, PhD", 
            "phone": "+46 46 16 56 75"
        }, 
        "overall_official": {
            "affiliation": "Clinical Trial Unit, SUS, Lund, Sweden", 
            "last_name": "Ulf Malmqvist, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden:  Swedish medicines product agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events", 
            "safety_issue": "No", 
            "time_frame": "64 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Peak plasma concentration of IdeS", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "source": "Hansa Medical AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hansa Medical AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}